Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Mar 26, 2020 |
| clinicaltrials |
| NCT02109627 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | terminated | Phase 1 | 17 | C. Babis AndreadisOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT02921061 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02892318 | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02316964 | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 8 | Sumithira VasuOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults(Japanese AML) | terminated | Phase 1 | 9 | Gilead SciencesINDUSTRY | 1 | Mar 6, 2020 | clinicaltrials |
| NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | terminated | Phase 1 | 23 | Polaris GroupINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01814826 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | completed | Phase 1 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01349049 | Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 90 | Daiichi SankyoINDUSTRY | 1 | Mar 2, 2020 | clinicaltrials |
| NCT03106428 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | completed | Phase 1 | 67 | MedImmune LLCINDUSTRY | 3 | Feb 28, 2020 | clinicaltrials |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 | 35 | ADC Therapeutics S.A.INDUSTRY | 1 | Feb 26, 2020 | clinicaltrials |
| NCT00783653 | Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years | completed | Phase 1 / Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | terminated | Phase 1 / Phase 2 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02044796 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 199 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01629082 | Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | completed | Phase 1 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | terminated | Phase 1 | 12 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01300572 | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | completed | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02995655 | CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | completed | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00321581 | AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02954653 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 8 | PfizerINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 7 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02909972 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 55 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)(ENTO in AML) | terminated | Phase 1 / Phase 2 | 148 | Gilead SciencesINDUSTRY | 3 | Nov 15, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT03126864 | Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | withdrawn | Phase 1 | 0 | Celyad Oncology SAINDUSTRY | 0 | Oct 29, 2019 | clinicaltrials |
| NCT01702155 | Phase I/II Study of DFP-10917 in Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 69 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT02809092 | Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 30 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT03672851 | Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia | terminated | Phase 1 | 2 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02674763 | Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia | completed | Phase 1 | 62 | ImmunoGen, Inc.INDUSTRY | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01160354 | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03395873 | Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy | terminated | Phase 1 | 7 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04008381 | Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia | unknown | Phase 1 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT00374933 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 31, 2020source: clinicaltrials